A defined skin test for detecting M. tuberculosis (Mtb) could have significant advantages over PPD in terms of sensitivity and specificity. Such a test could be used in persons infected with HIV, and could be used to distinguish Mtb from BCG immunization. We have identified new antigens of Mtb that stimulate human PBMC in vitro, and that elicit positive DH responses in the guinea pig model of tuberculosis. The goal of this proposal is to evaluate these antigens for the development of an intradermal skin test for the specific and sensitive detection of M. tuberculosis infections.

Proposed Commercial Applications

The market for a tuberculosis skin test is very large, exceeding $50,000,000 if it would be used to replace PPD. If it is used in a subset of infected individuals, such as HIV infected, the market would be smaller, but should still exceed $25,000,000 per year.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI041800-01A1
Application #
2776814
Study Section
Special Emphasis Panel (ZRG5-MBC-1 (01))
Program Officer
Ginsberg, Ann M
Project Start
1999-09-30
Project End
2000-09-30
Budget Start
1999-09-30
Budget End
2000-09-30
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Corixa Corporation
Department
Type
DUNS #
City
Hamilton
State
MT
Country
United States
Zip Code
59840